Jan Pilebjer

Simplexia is develops vaccine against herpes simplex virus type (HSV-2) infection, which is the most common sexually transmitted infection in the world. The infection causes genital herpes with painful and recurrent genital blisters. HSV-2 can also cause life-threatening encephalitis and meningitis in newborns and immunocompromised patients. A major issue is that HSV-2 infected patients also suffer a three-fold increased risk of HIV acquisition.

PExA is a Swedish award-winning company that develops and delivers a novel solution that address the rising need for biomarker identification and early diagnosis of lung disease through a technology enabling non-invasive sampling of human small airways. Watch the 2-minute video about PExA at www.pexa.se

Simplexia is develops vaccine against herpes simplex virus type (HSV-2) infection, which is the most common sexually transmitted infection in the world. The infection causes genital herpes with painful and recurrent genital blisters. HSV-2 can also cause life-threatening encephalitis and meningitis in newborns and immunocompromised patients. A major issue is that HSV-2 infected patients also suffer a three-fold increased risk of HIV acquisition.

PExA is a Swedish award-winning company that develops and delivers a novel solution that address the rising need for biomarker identification and early diagnosis of lung disease through a technology enabling non-invasive sampling of human small airways. Watch the 2-minute video about PExA at www.pexa.se